MAJI(.0349)...Exousia/Progenicyte possible acquisition targets......

The potential upside here could be pretty good, depending on how everything gets structured. One thing that does seem somewhat strange to me is the timing of the name/symbol change and potential acquisition of a biotech company. It is not clear yet whether the new incoming biotech will become the primary focus of MAJI going forward, with the marijuana-related business seeing a less prominent role or perhaps even a divesture of that business. Unless the incoming biotech is closely associated with the cannabis industry, I would think the new company would prefer another completely different name/symbol. Maybe the possibility of this new incoming company did not materialize until the name/symbol change was so far into the FINRA processing that they decided to just allow it to proceed.

Based on the limited information out there right now, my guess is that Exousia AI and/or Progenicyte could be the most likely acquisition targets. Progenicyte is involved in a lot of areas of biotech research/development, so I am not sure if MAJI would acquire the entire company, some type of spinoff from Progenicyte, or just license some of its technology.

Reason why I think those two companies seem like the logical targets: Prior to Mike Sheikh taking control of MAJI, the company had posted a tweet stating that the incoming biotech company was involved with a revolutionary drug delivery system. The tweet specifically mentioned the platform's use on glioblastoma (brain cancer). Sheikh does investor relations work for LUDG, which has a subsidiary called "Exousia AI". Exousia is involved in an exosomal delivery platform and just happens to be involved with a brain cancer study being conducted by Kiminobu SugayaI (Progenicyte). I find it rather interesting that Sheikh's email contact information on the MAJI OTC profile contains the word "exousia". As far as I am aware he does not use that particular email on any other company he is associated with. I suppose this "exousia" connection here could be nothing more than a coincidence, but it would certainly seem like an extremely strange coincidence.

Could be completely wrong with my guess, but this seems like the most logical scenario that I can think of at the moment. LUDG's 3/27/2024 press release has information regarding Exousia AI and the brain cancer study. I've placed some things of interest in bold.......

https://www.otcmarkets.com/stock/LUDG/news/Ludwig-Enterprises-Inc-OTCLUDG-Funds-Incurable-Brain-Cancer-Study?id=434885

https://www.ucf.edu/news/ucf-researchers-develop-novel-therapy-for-incurable-brain-cancer/

https://www.linkedin.com/in/kiminobu-sugaya/

https://progenicytetherapeuticsinc.com/

https://www.progenicytejapan.com/exosomes/

INNI(.0103)...potential merger with Xosqe......

Still holding my full position in the INNI shell and hoping this turns out well. The large share increase as a result of the advisory agreement (disclosed in the 8/13/2024 10-12G) and change in control back in July is not the most ideal situation and complicates things. Also, allowing the stock to become delinquent in its filings is certainly disappointing, raises uncertainty, and puts a damper on the share price (Schwab investors are not allowed to purchase shares because of the limited tier status).

But the potential merger candidate (Xosque Inc. -- Xosque Media) does look pretty interesting. Some of the people involved with Xosqe have impressive backgrounds and connections........

Xosqe Inc CEO: https://www.linkedin.com/in/marco-frazier/

Xosqe Media CEO: https://www.linkedin.com/in/arunmaljaars/

Xosqe/INNI investor: https://www.linkedin.com/in/ezzatjallad/

https://xosqe.com/

https://www.xosqemedia.com/

STJO(.017)...restructuring, debt reduction......

71.89M outstanding
27.46M unrestricted
11.12M DTC

STJO issued an interesting press release yesterday. Depending on the undisclosed details of these moves, the restructure of its operations and the significant reduction in debt could be a nice catalyst. From the press release.......

https://www.otcmarkets.com/otcapi/company/dns/news/document/78477/content

https://stjocompanies.com/

Phoenix's Nasdaq intentions......

Phoenix does fully intend on getting a Nasdaq listing at some point. This was confirmed by Sheharyar Haider Malhi (Phoenix CFO, TCRI director) during the Phoenix Q3 2024 conference call. I did not take notes while listening to a replay of the call so I am just going by what I can remember. When responding to a question regarding whether Phoenix has any plans to obtain a listing on Nasdaq, Malhi said "absolutely". He said it wasn't a top priority or the primary focus of the company at the moment. So the timeline of when they might apply is unknown.

Exactly what Phoenix intends to do with the TCRI shell is indeed the big question. It would have been pretty wild and fun for us TCRI shareholders if Phoenix would have proceeded with its original plan of going public via TCRI rather than pursuing an overseas listing. But I remain optimistic and bullish on the prospects of TCRI as long as Phoenix continues to have involvement with this shell.

The three most probable scenarios, IMO: 1) Phoenix hired Charlie Faulkner and Simon Wajcenberg with the intention of having them basically implement their original Edgemode plan (cryptocurrency mining, high performance computing data centers) in the TCRI shell, with the assistance of Phoenix. One of the sites would likely be located in Carolina. 2) Phoenix has intentions of transfering one or more of its US-based hosting sites to the TCRI shell. One of its Carolina sites would probably be the most likely. 3) Phoenix wants Charlie and Simon to basically turn TCRI into a technology holding or venture investment type of vehicle, which is something they both have experience with.

The reason I mention the possibility of TCRI becoming involved with some type of crypto mining or data center in either North or South Carolina: If you do a right-click "view page source" on the Techcom website (https://techcom-inc.com/), you will find language referencing "Carolina site #1". It is known that Edgemode had plans for a site in North Carolina. Phoenix has at least one site in South Carolina (possibly another 3 under development there, but I am not entirely sure about that). As far as I am aware, this language has been on the TCRi website for quite awhile......



I think it is a given that most retail TCRI shareholders (myself included) probably would feel much more comfortable if Carl Agren and Sheharyar Haider Malhi were in the roles of CEO/CFO here at TCRI instead of just directors. But as noted in previous posts, Phoenix has the final say in any debt obligations that TCRI enters into. That certainly does not guarantee that any catastrophic decisions might not be made here but it does provide at least one level of potential safeguard. I think it is reasonable to assume that Munaf Ali or other Phoenix executives know Charlie and Simon well and are aware of any successes/failures they have had in their business dealings. So I am willing to defer to Phoenix's judgement call on TCRI's management, until proven otherwise.

TCRI has the potential to become a very valuable asset for Phoenix if everything is handled correctly here. I have my fingers crossed that the next TCRI catalyst will be reasonably good.

KSEZ(.75)...Adam Gefvert position, financing......

The OTCQB certification filing that KSEZ made last week contains a couple of items worth noting.........

Adam Gefvert: According to this filing, Adam Gefvert (White Diamond Research) owns 1.2M shares as of November 7, 2024. I think that is quite interesting.

https://www.linkedin.com/in/adam-gefvert-cfa-1632ab24/

https://twitter.com/Shiningboy?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

Financing: The conversion price on the consultant debt is now at 50 cents. The conversion price is based on the most recent closed PPM (private placement memorandum). As far as I am aware there has not yet been any 8-K or press release disclosing/confirming a private placement at 50 cents. If you recall the previous placement ($500K) and debt conversion was done at a price of 5 cents. So this is a significant and bullish increase.

The modified agreement between KSEZ and the consultant (Coral Investment Partners -- Erik Nelson) from earlier this year (3/6/2024 8-K/A) has the following terms/conditions, which coupled with the info in the certification filing would strongly suggest that KSEZ may have raised at least $500K at 50 cents.......

Possibly a week or so ago.......

I don't recall when I first noticed it, but I think it has been there for maybe at least a week or more (not really sure). I don't have a premium subscription to LinkedIn which makes it harder and more time consuming to get relevant information. Usually I have to use a combination of information on the site and Google searches to find out identities and get some more useful info. When I first noticed that there had been another employee added, I only did a very quick/light search and didn't really take an in-depth look at each individual profile that might have a connection here. Based on those initial searches, I just assumed that most of these people were likely not connected to TCRI and were employees of a South American telecom type of company.

But when you brought the subject up, and I remembered that the number of people following Techcom on LinkedIn had increased by 1 or 2 people in the last week or so, I decided to go through some more of the individual profiles that were hitting on my Google searches. Some I could dismiss right away because they were clearly connected to a different Techcom company. Some were unclear if they might be connected. That is when I noticed that Melanie had connections to this Techcom/TCRI company (correct logo and link).

New employee(s).....interesting......

I am not really sure what to make of the new employee(s) that has shown up on the Techcom LinkedIn profile. If that LinkedIn member profile is accurate (she actually is employed by TRCI and is following TRCI), then that certainly is a solid sign that something is occurring at the company. Exactly what that something is remains to be seen.

The only reason I have a question about the accuracy is because there has been some situations at LinkedIn (albeit few) where either the member made a mistake or some type of glitch at LinkedIn had the wrong company link in the profile. That is something that could happen here because there are quite a few companies out there that have "techcom" in their names.

If this is accurate, it is definitely interesting and another sign that some type of corporate development might be drawing closer........

https://www.linkedin.com/in/melanie-gutierrez-laura-4177b3323/?originalSubdomain=cl

FUSTD(.30)...accumulated more shares......

13.3M outstanding
3.5M unrestricted
932K DTC

Since my last post about FUSTD, I have added to my position at mostly 21 cents and higher (prices adjusted for the recent 1:5 reverse split). Added 20K shares yesterday around this 30 cent area. I can't say that I am completely comfortable buying this stock with a bid/ask spread of 100%, but the risk/reward around this 20-30 cent area looks pretty interesting to me. I think I mentioned in one of my previous posts that the market lately has been rewarding investors who are a little more aggressive with their buying, so I am willing to take a chance here. Every time I look at this stock I get this gut feeling it is going to have one of those 5-10 bagger kind of moves that we have seen in the OTC this year.

The only unusual thing I have noticed recently is that around the time they filed for the RS on Nevada, this Shopify account belonging to a company called "Fuse Group Holding" started showing up in my Google searches. If you look at the "privacy policy" info on that account, you will find the address matches. Not sure if I should have good, bad, or indifferent feelings about that......

https://pspluscode.myshopify.com/

With FUSTD it is almost impossible to guess what might be happening. Over the years the company has struggled to complete acquisitions/mergers or develop a solid/coherent business direction. On the consulting side of their business, the last agreement they disclosed back in December was with a Chinese company involved in things like generative artificial intelligence.

But with this relatively attractive share structure, a recently completed reverse split, a history of large moves in price, and a history of Asian investors involved in the stock, I want to have a nice position established just in case this has a really nice move at some point.

Wajcenberg...recent LinkedIn post/comment activity.....

Simon Wajcenberg made some LinkedIn posts and a comment in the last week -- all of them regarding artificial intelligence data centers. He specifically mentioned EdgeMode in his comment, so I am assuming the statements he made in his posts are also in reference to EdgeMode. Interesting to note that Charlie Faulkner is one of the people who "liked" Wajcenberg's comment. Similar to my previous post, I just find the timing/nature of these posts/comment to be a little interesting and makes me wonder if this is a sign that some type of corporate development for TCRI continues to draw closer.

Wajcenberg's posts.......

Wajcenberg's comment.....



https://www.linkedin.com/in/simonwajcenberg/

Endorsements on a LinkedIn profile can be relatively meaningless for various reasons (sometimes they are just done for purposes of expanding exposure/connections in the business world), but it is kind of interesting to note that Joseph Lambert is one of the people who recently endorsed Wajcenberg......

https://www.linkedin.com/in/eqchocapital/

TGRP...2024 price decline, clinical results, etc......

On another board I made a few posts that kind of delve into that price decline and why I like TGRP. Reading those posts will help make some of my statements/comments below a little clearer......

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175083722
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175106246
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175094857

I have followed TGRP to varying degrees since the reverse merger in August 2022. I've always found it to be a pretty interesting situation that never really got much in the way of investor attention (in part because of the overall poor OTC Market conditions the last couple of years, and perhaps in part because its price/valuation around that 50-60 cent area made investors a little more cautious).

I do think the Schwab/Ameritrade merger and the restrictions on buying TGRP had some role in that price decline we saw in TGRP this year. There is a very close correlation between the date of when Schwab finished integrating the Ameritrade clients and the date of when TGRP's price decline started. Schwab finished integrating the final Ameritrade clients around the middle of May 2024. Beginning around the middle of May all of the Schwab/Ameritrade investors were now unable to place buy orders for this stock thanks to Schwab's buying restrictions. TGRP's price decline started about a week and a half after that final integration occurred. Schwab lifted those buying restrictions sometime around September 12/13, and that is when the price started moving up strongly. If selling pressure shows up on a stock where large numbers of potential investors are not allowed to place buy orders, it is probably going to have a negative impact on the share price.

Now, as to why there may have been selling pressure on TGRP at sub-penny prices that is a question I don't have a definitive answer to. Could be something negative that I am not aware of, maybe some investors just got tired/concerned and wanted to move on, or maybe there were some forced liquidations because of margin accounts. In the two years I have monitored this company/stock I have not yet seen anything that has negatively changed my overall positive thoughts about TGRP.

Regarding those Phase III clinical trial results: Let me preface this by saying I could be completely wrong about my understanding/interpretation of this trial and its results. But I have always been under the belief that the basic overall survival results of this particular Phase III trial did not meet whatever endpoints the investigators were hoping to achieve. That was the conclusion of the lead investigator in an ASCO abstract back in May 2023 (see below). Again, I could be completely wrong about this or maybe there are some positive secondary/tertiary objectives that could make some of the final study results look better.



https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.5502

I think focusing solely on whether any one particular trial or any one particular drug has positive results might not be the best way to look at this investment. I think it makes more sense to look at this company and stock with more of a wide/broad perspective. TGRP has involvement in quite a few ongoing clinical trials and more in the pipeline from what I understand. I don't closely monitor all of their trial end dates, but off the top of my head I think their study for laser-assisted delivery of NanoDOX is scheduled to end in November. The Phase I cancer trial for Aza-TdCyd was estimated to end yesterday. If I recall correctly I think there were at least another 1 or 2 trials that had estimated end dates before February 2025.

All of TGRP's corporate activity in the areas of clinical trials seems to be done in a relatively cost-efficient manner and with relatively minimal risk to the company. So TGRP could have poor results on multiple clinical trials and it really should not sink the company like it might on other biotechs. That is how I look at the company anyway.

As I mentioned in one of the posts above, TGRP's subsidiary (Alchem Laboratories) continues to get government contracts. The latest one is a 7-year almost $50M contract which was awarded to Alchem around 2 months ago. Regarding the biodefense aspect of TGRP, it is perhaps worth noting that Alchem co-hosted the first meeting of The Consortium for Nerve Agent Countermeasure Research about one month ago. There was a tour of the Alchem facilities and CEO James Talton talked about drug discovery......

https://www.cnacr.org/symposium/2024/

The pullback recently has been a little bigger than I would have liked to see (would have preferred to see the stock stay above the 10-cent area), but I remain pretty optimistic on how this will turn out. TGRP is in an interesting sector, the price/valuation is still reasonably attractive, the stock has shown it is capable of an explosive move, and there are possible multiple catalysts in the coming months or so. The OTC market has been a little more receptive toward these kinds of plays this year so I remain comfortable holding a position.

LNBY($1.71)...increased position......

30M outstanding
331K unrestricted
56K DTC

I have been increasing my position in LNBY since I made the above post. Bought more shares in the .93 to $1.5433 range, with some nice blocks down around that $1 - $1.10 area. Current cost basis on my position is under 75 cents per share. Although LNBY did reach on low volume the kind of price area I was initially anticipating, I think the setup here is so interesting that I am willing to roll the dice and look for higher prices.

LNBY basically checks the boxes on some of the things that have worked very well for investors in the kind of OTC environment we have seen relatively recently. It is a stock that has recent/current catalysts and is still pretty much off the radar screens of most investors, it is a stock with China/Asia connections, and it has a low DTC number at the moment. Given how difficult it can be to accumulate LNBY, there is some definite explosive capability in this stock if buying interest increases.

At this point I am not really sure whether the entire company of Xinsheng New Media is going to be the RM target and new business direction, or perhaps just part(s) of it. That is often the problem with a lot of these China/Asian reverse mergers. Sometimes all of the due diligence points in a specific direction but when everything gets finalized you don't get exactly what you were expecting. That kind of thing can be pretty annoying/frustrating. I haven't been able to access the Xinsheng website for awhile and its main Douyin account appears to have been taken down or can no longer be accessed by search. From time to time I still run across some things on Douyin or Google searches that make me remain bullish on the stock.

Based on this paragraph/catalyst in the quarterly filing from mid-August, it is currently my belief that at a minimum LNBY will be involved in the artificial intelligence aspects of Xinsheng (software and edge AI robots). Perhaps worth noting: When the artificial intelligence division of Xinsheng held an introductory/presentation type of event back in December, apparently representatives from 5 major banks in China attended that event.

TRCC(.69)...picked up some shares.......

4.04M outstanding
130K unrestricted
57K DTC

I bought 10K shares of TRCC today under 50 cents. It probably would have been more prudent to sit around the bid for awhile and see if I can get better prices at some point, but in the current OTC environment I figured it might be wise to just go ahead and secure some shares here around this 50-cent area. I can always try fishing for cheaper shares now that I have at least a few "core" shares in hand. Quite a few of these tightly-held, low DTC types of plays are turning into huge winners and rewarding investors who are a little more aggressive with their buys.

Let's see if this one has a really nice run in it at some point this year or early next year. From the 1-SA that was filed today........

https://www.otcmarkets.com/filing/html?id=17846722&guid=82L-k6OMvwFaJth

Clarification on my previous post.......

What I was referring to in the bold part of my previous post was Schwab's buying restrictions on ANKM. I had wanted to try and get some shares of that company around the $2 area after it experienced a change in control recently. It is an OTC QB stock, and it is current and fully-compliant with both its SEC and OTC obligations. Schwab has the exact same buying restriction on ANKM as it had until recently on TGRP.

It just seems so totally ridiculous to me that the brokerage will allow me to place a buy order for some very obscure limited tier stock (GJST, for example). But if I want to buy a "quality" and fully-current OTC QB stock like ANKM, Schwab will not allow any buy order. This is the kind of idiotic inconsistency I was referring to.

I-R...TGRP, still holding position, brokerages......

Maybe it is not the smartest thing to do after such a large move, but I continue to hold my full position (500K shares at a cost basis of under .0147 per share). I went into this play with personal expectations of getting at least somewhere in the 50 cents to one dollar range. Nothing I have seen so far has changed my goal.

It looks like the volume on the move in the .30 - .40 range today was small (around 40K shares just from eyeballing it). It did not seem to take much volume at all to move the stock in either direction today, so I view that as somewhat encouraging (shows it could have some of the explosive capability a person might expect from a biotech/biopharma play with a relatively low DTC number). If it can churn a little bit around this 15-cent support area, I think that would make for a pretty decent set-up for a much stronger push into/over that 30-cent area.

I have my fingers crossed that the heavy selling that occurred at or around the sub-penny level back in July/August was more of an aberration rather than an indication of something terribly wrong with the company or stock. It is my belief that TGRP's drop in share price from 50 cents to sub-penny in the last four months was influenced to at least some extent by the inability of Schwab investors to purchase the stock. If other brokerages had similar buying restrictions, that could certainly have contributed to the decline. I think it is entirely possible that TGRP would never have dropped under 5 or 10 cents if all investors had been able to place buy orders.

The broker policies on restricting buying on some OTC stocks is a continual source of investor irritation/frustration. I had asked a Schwab representative a few weeks ago about the TGRP situation (and the general inconsistency the brokerage has toward buying OTC stocks, especially the limited tier stocks). Not surprisingly Schwab has the same attitude as OTC Markets. They both basically consider themselves gods. They have the power to determine what you can buy, when you can buy it, and don't believe they need to defend/explain their policies to the peasants.

I don't know how other brokerages handle the OTC (I'm sure they all have their positives/negatives) but Schwab sifts through the limited tier OTC stocks and cherry picks which ones it will allow investors to buy. It almost seems like they just throw darts or flip a coin to determine if they will allow buys. Common sense tells me that if I can buy one limited tier OTC stock, there really shouldn't be any reason why the brokerage can't lift buying restrictions on all limited tier OTC stocks. And if they are going to allow buys on some limited tier OTC stocks, I don't think it asking too much of the brokerage to allow me to buy a fully-compliant, SEC-reporting stock trading on the OTC QB. All of this inconsistency needs to come to an end, and brokerages need to restore decision-making and freedom back into the hands of the investors.

Maybe I am just crazy or my thought processes are just too radical for these modern times.

TGRP(.075)...Alchem's most recent contract......

TGRP's subsidiary received a 7-year, almost $50M government contract around the end of July this year.



https://www.alchem.com/contracts

FUST...added...TGRP...entry/accumulation......

FUST(.0491): Added more shares this week in the .048 to .051 range. Still think the risk/reward from around this price area looks pretty attractive to me given this stock's history of impressive 10-bagger moves.

TGRP(.0225): Accumulated a nice position in TGRP yesterday in the .006 to .02 range. Schwab had a buying restriction on TGRP for a very long time, even though TGRP has been fully current in its OTC filing obligations for quite awhile if I recall correctly. When TGRP dropped down to around the 3-5 cent area a couple/few months ago I tried unsuccessfully on an almost daily basis to get a buy order accepted. I think Schwab must have taken TGRP off the restricted list sometime late Thursday. I am pretty sure I tried entering a buy order Thursday morning and/or early afternoon but it got rejected.

Hopefully TGRP found its bottom here recently. I really like the upside potential. It didn't receive a lot of investor attention at the time but CEO James Talton made another move/acquisition earlier this year that I think increased the overall attractiveness of the stock/business. He brought his other company (Alchem Laboratories) under the TGRP umbrella with relatively small dilution. Alchem is an interesting revenue-generating company involved in drug research/development and contract manufacturing. It has a history of securing or participating in government contracts and has done business with quite a few other biotech/pharma companies.

https://www.nanopharmaceutics.com/

https://www.alchem.com/

AFDG(.0065)...Q4 potential catalyst, uranium.......

The catalyst I mentioned in the above post/thread turned out to be a complete flop. Any potential of the VCXA/AAGR play adding some nice value to AFDG was pretty much destroyed with the basically immediate and unrelenting selling of AAGR. The lack of institutional/investor support on AAGR was about as ugly as it gets.

So AFDG is now moving on to the next potential catalyst, which is expected to occur in the fourth quarter. I picked up some more shares yesterday at .0065, current cost basis on my position is now a little over .0087 per share. Maybe this move into the uranium sector is something that will eventually produce a nice move in the stock. From the press release that AFDG issued on July 9......



https://www.otcmarkets.com/otcapi/company/dns/news/document/75829/content

TCRI(.09)...Faulkner updated his LinkedIn profile......

Perhaps worth noting that Charlie Faulkner updated his experience section of his LinkedIn profile about a week and a half ago (it shows he is still the active CEO of TCRI). This is the first time since his November 2023 appointment as CEO that a reference to Techcom has appeared anywhere on his profile page. It is also worth noting that Techcom is now one of the companies that he is following.

Maybe these updates are merely some long-overdue "housekeeping" items on his profile. But the timing/nature of these updates suggests to me the possibility that some type of corporate development might be getting closer.

So far this year I haven't had any luck getting fills on buy orders I have tried at prices below ten or eleven cents.

https://www.linkedin.com/in/charliefaulkner/

FUST(.076)...accumulated position, history of large moves.......

I started accumulating a position in FUST when the stock dropped down to around the 5 cent area in June/July (currently averaged in at .0506 per share). Over the last few years FUST has experienced 4 very large moves from its bottoms (at least 10X or higher). The first move occurred during the pandemic when it looked like FUST was going to acquire a biotech company in 2021. The next 3 large moves have all occurred in basically the last year or so. What probably contributed to some extent to these 3 recent moves was the fact that a Malaysian company had around $717K worth of FUST convertible notes and elected to convert those notes at 45 cents. I think it might be worth noting the same Malaysian company still has a $50K convertible note (convertible at 45 cents) sitting on FUST's books.

My thinking is there is going to be some type of catalyst at some point (either another note conversion, progress in the areas of acquisitions or business, etc) that will trigger another large move in the share price. If FUST can find a bottom somewhere around this 5 cent area (and they don't enter into some kind of very ugly financing), I like the potential of getting at least a 5-10 bagger on my current position. The risk/reward looks pretty interesting to me.

INNI(.017)...finished accumulating position......

Picked up another 200K shares at .0138 today. Hopefully sometime in the next couple of weeks or so I will be able to look back and say this was the correct decision to make. A lot of potential risks here, as is customary with most shells/RMs (for example, legacy share dilution, lackluster RM target, poor market conditions, etc).

But from a legacy share valuation standpoint it makes sense to me to have my position built around these kinds of prices/valuations. Heading into whatever company disclosure is coming here, I have a cost basis under .0162 on my position. I have my fingers crossed that the legacy share count will remain somewhere around that 17.6M to 22.6M share area, which would be a legacy valuation in the neighborhood of $280K-$370K. I think there is a half-way decent chance of making some nice money when buying into shells/RMs at those kinds of legacy valuations.

INNI/MAYX...added to positions......

INNI(.018): I bought another 200K shares at .0183 here recently, following the 1.97+B increase in outstanding share count that was disclosed late last week. I assume a change in control has now occurred and we should be getting some more information fairly soon. Not sure if it will be disclosed in a supplemental filing or if they plan to wait and disclose it in the upcoming quarterly filing which will probably get filed within the next couple of weeks. If this is a RM, it looks like the legacy shareholders would probably retain basically 1% of the post-merger company. With that large of an increase in the outstanding shares there is obviously some additional risk that the upside potential might be negatively impacted. But I think it is worth rolling the dice a little bit and increased my position.

If I look at this situation as it stands right now, and take a conservative approach to the analysis, I think this play has a chance of reaching at least $1M on its legacy share valuation. If the legacy share count remains around the 23M number, then I think it is reasonable to believe this play has a chance at seeing minimum prices of 4 or 5 cents. Ultimately a lot is going to depend on the overall quality of the RM target and the final structure.

A couple of interesting things about this INNI situation: As I mentioned in the above post, I continue to find it interesting that David brought on an auditor for this shell. I also find it somewhat interesting that he kept INNI as a Delaware corporation. I don't know if there would have been any issue that prevented him from making a change, but I do find it a bit interesting that he never switched the registration to another state like Nevada. From everything I have heard and am aware of, I think Delaware is a particularly expensive/difficult state to have a company registered in.



MAYX($5.99): Picked up another 1K shares around $4.50 after the change in control to Orbit Beyond a couple weeks ago. Based on the quarterly report filed last week, it looks like the legacy share count heading into the RM has been adjusted up to 550K shares. Given the nature and overall quality of the incoming company, I think it would be completely reasonable to believe this is a shell/RM situation where a legacy share valuation of at least $7-10M might be possible. That should easily offset any concerns I had in the above post about potential dilution of the legacy shares. Absent any really ugly final structure on this reverse merger, I am looking to get at least $12 on my position. Certainly has the potential for some explosive upside if the shares remain tightly controlled and the market conditions are favorable.

FWFW(.45)...disposal/acquisition transactions a couple of weeks ago.......

29.6M outstanding
452K unrestricted
400K DTC

I increased my position in FWFW yesterday by buying a little more than 15K shares at sub-45 cent prices. Ideally I would have liked to just bid sit, but my experience over the last couple of years on FWFW (difficult to buy, my high bids getting passed over, etc) made me want to be more aggressive with my buying.

FWFW disposed of its primary asset/business (QBS System) a couple of weeks ago and acquired a 9.38% equity position in Flywheel Financial Strategy (FFS). This is the company that was supposed to be the reverse merger target when Roy Tang first gained control of the shell. And that is what I thought I was buying into when I first started purchasing shares back in 2022. But they never actually vended FFS into the shell, and instead they acquired QBS System and also started forming a robot distribution company. To complicate matters, throughout all of this time the management/company has made it sound like the reverse merger between FWFW and FFS did in fact take place. So this has made for a somewhat confusing/puzzling situation over the years.

I don't know if they are now planning to acquire control of FFS or if these transactions are just part of some broader corporate strategy. The timing for entry/accumulation just seems particularly attractive to me at this moment in time. Investors seem to be a little more receptive recently to some of these low float plays. Given the current relatively tight share structure, and the fact that there appears to be some increase in corporate activity taking place, I would like to have a position built before any more potential catalysts might appear. It would be nice if FWFW turned into one of those sub-50 cent to multi-dollar type of plays.

Involuntary-Recluse...hopefully the SYBE tier change is just temporary.......

I kind of figured it was going to be a challenge for SYBE to get that quarterly filing done within the deadline(s). My fingers are crossed that the SYBE filing delinquency is not completely a result of management incompetence and they will get back to being current relatively soon. Hopefully it will turn out that this was primarily a result of SYBE being forced to change auditors because of that SEC May 3 ban on the Borgers auditing firm. If that auditing change and the delays it may have caused are to blame here, SYBE's trip to the Expert Market is an example of the kind of damage/fallout I was concerned about in a post I made a couple of months ago over on the ECGR board.......



https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174359682

It just seems ridiculous to me that the SEC and OTC Markets were not willing to provide affected companies with additional time beyond the normal extensions and grace periods. When you ban an auditor just 12 days before the Q1 reports were due, that doesn't give companies much time to select new auditors, have the auditors do their review of the quarterly, and get the filing uploaded in time. Would it be so bad for the SEC and OTC Markets to display a modicum of discretion once in awhile before they are so quick to deal out punishment to companies?

I am not prepared to panic right now regarding my position in SYBE. I'll give the new management some leeway and the benefit of the doubt for awhile because I know this is an unusual situation that other companies have found somewhat challenging. For example, I think one of the Asian stocks I am bullish on (FWFW) was definitely affected by this auditing change requirement. This is a company that usually files its periodic reports on time or within the normal SEC-provided extension. When this Borgers auditor ban was announced, I think much of FWFW's management was over here in the United States (attending the Berkshire Hathaway annual meeting, visiting tech companies, etc). The company had to scramble and find a new auditor and just managed to get their Q1 filed on the final day of the OTC Markets grace period (it took more than 2 months longer than they usually file).

SYBE(.0595)...accumulated a position.....

99.4M outstanding
3.03M unrestricted
1.25M DTC

SYBE had a change-in-control back around mid-April. I have accumulated a position in SYBE over the last couple of weeks or so. Currently averaged at a little under 4.2 cents per share (bought in the range of .0259 to .0599). The initial pop in share price following the control disclosure seemed to be smaller than I would have expected to see. I'm not sure if that was merely a result of poor market conditions or a reflection on the quality of the incoming company/management. Or a combination of the above.

There are the usual risks associated with a shell/RM here (details on the final structure and the incoming company are not clear yet, possible financing needs, etc, etc). It is always possible that the new control entity is just an intermediary rather than the RM target, which can complicate things when you do an analysis of the play. Plus we have the added thrill of a filing delinquency. A lot of things could dramatically change and go wrong here, but the risk/reward looks reasonably attractive to me right now. If I am looking at things correctly, Worldwide Holdings Investment Group now controls more than 95.5% of the SYBE shell. That leaves a legacy share count of a little over 4.4M shares. At the current price of 6 cents that is a legacy valuation of well under $300K. That kind of legacy valuation combined with the current share structure makes SYBE pretty hard to ignore.

I think this has the potential for some significant upside if the new management handles this merger in a shareholder-friendly manner. That is probably asking/wishing for too much, but you just never know which company/investment might pleasantly surprise you. The setup here is certainly intriguing. I will be disappointed if I walk away from SYBE with anything less than an average of 30 cents per share on my position.

Worldwide Holdings websites.......

https://wwhcorp.com/

https://wwhgroup.net/

SYBE CEO Jeremy Davey.......

https://www.linkedin.com/in/jeremy-davey-420120/

YBGJ(1.04)...holding some shares for possible move higher.......

YBGJ had a high-volume pullback in late April, and has now moved back up nicely to an area of some resistance on the chart. I've been holding a position in YBGJ for a couple/few years. Sold a little under half my position (mostly in the .85 to $1.02 range) on this most recent move. Still holding some shares with a 10-cent cost basis and am looking to see if there will be more of a stronger move above this $1 area.

This movement in YBGJ is somewhat interesting in light of the massive move that LDSN experienced recently (sub 3 cents to over 90 cents). Maybe LDSN will ultimately turn out to be just a stock-specific situation but I am hoping that the LDSN performance might be a harbinger of increased interest in some of the Asia-related OTC stocks. We have seen the kind of wild/crazy moves many of the Asian stocks tend to have on Nasdaq. It would be nice to see some of that happen again down here in the stock sewer.

INNI/MAYX...added to INNI position, still holding full MAYX position......

Accumulated some more shares of the INNI shell today to add to a starter position I had bought awhile ago. Although INNI still has the disadvantage of the name/symbol and 15-12G filing issues that I mentioned in the post above, I am thinking maybe the timing for entry/accumulation on INNI is looking a little more interesting right now. I'm not real confident about it, so I've kept my purchases mostly around this 1.5 cent area on the INNI shell. The legacy share valuation at that price area seems reasonably attractive to me and should provide some decent upside if David Duarte (Tailored Tickers) can find a RM candidate for the shell.

The reasons I have decided to add to my position now......

1) The other most comparable/similar Duarte shell (AFFL) has been trading recently at a valuation that is basically 2X what INNI trades at. So between those two shells INNI is significantly undervalued right now.

2) I do find it somewhat interesting that recently David chose to have INNI's financials audited. Maybe I shouldn't read too much into that, but that seems to be very different from how he has handled his other shells.

3) On one of his other shells (MAYX) around 920K shares were added to the outstanding share count this week, which increased the total outstanding to 1.3M shares. I don't know whether those shares are part of a RM transaction, or if they might be for things like services rendered. The statements in the MAYX periodic filings seemed to make it fairly clear to me that the MAYX shell was probably going to complete a RM sometime this year (see below), so with this share increase this week I think it is somewhat logical to assume/guess that there may be a change-in-control with the MAYX shell right now. As far as I am aware, there has not been any announcement/disclosure yet regarding the details on that share increase, but if the MAYX shell has indeed been sold my thinking is that this could bring some additional investor attention to his other shells. From the MAYX filings......

Regarding MAYX: I was able to buy a nice amount of shares in the $1.25 to $1.50 range back in March. At that time Tailored Tickers controlled around 300K of the 380K total outstanding. From an overall structural/valuation standpoint, the possibility of a forward split, and a RM timeline that could be relatively short, I figured the MAYX shell was pretty attractive. When I first bought in I set a personal price target range somewhere around $4 to $18+, depending on how many shares Tailored Tickers decided to retain in a reverse merger. I would need to adjust those price targets significantly lower if those 920K shares turn out to be merely a dilution of the legacy shares position and not directly connected to a RM target. It is not an easy/comfortable thing to do in this anemic/difficult OTC market, but as of today I am still holding my full MAYX position.

LNBY(1.31)...potential RM with Xinsheng New Media......

I purchased some shares of the LNBY shell in late April at 40 cents. The sale of the control block (a little under 29.4M shares) was completed on April 23. I believe there are around 400-600K legacy shares (of which about 205K are owned by the previous owner and her husband). As with any reverse merger the quality of the RM target and final structure of the deal will be crucial. But the risk/reward looked pretty interesting to me. If the final legacy share count does turn out to be around this 400-600K level, then I think LNBY has a fairly decent chance of seeing prices at $3 or higher.

The reverse merger target appears to be Xinsheng New Media, and it seems to be fully-intent on reaching a listing on the Nasdaq by the end of 2026. Apparently it is already working with a company that has assisted other Chinese companies in getting Nasdaq listings. Xinsheng is heavily involved in live e-commerce education and talent, involved in things like movie/TV series production (with an emphasis on short-form kind of content that can gain popularity quickly and generate revenue on social media platforms), edge AI robots, etc.

I don't know how realistic their revenue projection is, so take the following information for what it is worth. If I am interpreting/understanding the company development path timeline and numbers correctly, Xinsheng New Media is projecting that by the end of 2026 the company will be generating around $2.75B US dollars in revenue.......

The Douyin (TikTok) account for the company is active and has recently been showing videos of companies and government organizations visiting the company headquarters to learn more about the business.......

https://www.douyin.com/user/MS4wLjABAAAAXNqDlziv-5wa_zHn5YpjsgPeOrZ3XE9rwc-dzLpMr6FhOrVKcOkaP2bcBVeoSFiN

Xinsheng New Media website......

https://www.xsnewmedia.com/

ECGR...risk/reward still looks attractive.......

There is no question that the overall state of the OTC Markets has been frustrating/dismal for a number of years now. The combination of policies from the SEC, OTC Markets and brokers have pretty much left this part of the market in shambles. The continual lure of liquidity in the Nasdaq and crypto markets have contributed to the problem in the OTC. And now we have more and more OTC companies that are having difficulty maintaining their filing obligations or just flat-out abandoning their listings. All of this has made it extremely difficult for retail investors to make any meaningful money down here in the OTC.

The damage to the overall OTC market may very well be permanent at this point, but hopefully there will still be brief moments and stock-specific opportunities that make it worth monitoring at least a little bit. I still think ECGR could be one of those reasonably nice opportunities. The SEC's ban on auditor BF Borgers on May 3 certainly throws in a complicating factor for Borgers' OTC clients like ECGR. I don't know what kind of damage/fallout over the next few weeks/months this will cause for the OTC and Nasdaq stocks that were using that auditor, but I will probably consider adding to my position at sub-10 cent prices if there is significant weakness in ECGR.

Maybe I am viewing ECGR through too much of an optimistic or bullish lens, but I see some things here that intrigue me a little bit: Insider and institutional (Ionic Ventures) participation in the financing at 5 cents, eventually a name/symbol change will get completed, eventually a 15c2-11 statement will be filed to restore quotes, the consultant has included a cause in his agreement that prohibits ECGR from using toxic financing, etc.

Kinetic Seas is a company that is still relatively early in its development stage. Yes, there are aspects to the business that might be considered somewhat boring, but there are also aspects to its business plan that could turn out to be quite interesting. The cloud hosting and data center part of the business is something that could open the doors to potential partnerships and acquisitions in the artificial intelligence space. From the 10-K.......



There will certainly be more financing/dilution here at some point for expansion of the data center capabilities and business operations. Terms/conditions of any future financing will be pivotal to this investment success or failure. I don't see the company debt right now as being something to be overly concerned about. The consultant controls most of the $200+K debt as of the last periodic filing. Since he already converted some debt at 5 cents back in December, my expectation is that he will continue to convert at that price or higher. The consultant's one million warrants can be exercised at $1 and $2.50, so any dilution from those would be relatively small. If the institutional investor that purchased shares at 5 cents wants to run the stock at some point, I have a feeling they would be able to do it quite easily.

I still have expectations of getting at least 40-50 cents on my position......

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173990705

GRHI(.08)...upcoming exposure for Loot8/GRHI......

GRHI is currently seeking some financing (as per CEO Marcus Daley in his February 29 Starlight Capital presentation). So obviously some additional risk exists here until the terms/conditions of any financing are revealed. I am still holding my full GRHI position and looking for a more solid/sustained push over that 10-cent level at some point (fingers crossed). Activity at the company appears to be ramping up. Loot8 should be coming out of beta testing probably this month or early April. Once this round of financing is completed, and the app emerges from beta testing, I am semi-expecting to see a noticeable increase in news flow and media exposure as more universities/institutions/commercial clients become involved with Loot8.

Co-founder Scott Page is scheduled to appear and represent Loot8 on a Spaces tomorrow (March 11). Praise (a crypto token) is arranging the Spaces, featuring key opinion leaders and startups in the crypto/Web3 industry.......

https://twitter.com/praisetoken

CEO Marcus Daley's Starlight Capital presentation on February 29, begins around the 40:30 mark.......

ECGR(.17)...institutional investment, anti-toxic financing clause......

Added to my position yesterday with some blocks around 16 cents, following the release of an amended 8-K. Most of my previous purchases were made around 10 cents. There is some risk that the consultant might receive significantly more shares over the next year and the company will likely need additional financing, but overall I think the risk/reward continues to look fairly interesting to me. The artificial intelligence sector should continue to produce some decent gains. I've been very pleased so far with my investment in GLAI (formerly WSCO), and I think ECGR has a chance to do quite well.

Depending on exactly how I want to look at it, I figure ECGR has roughly 3-4M legacy shares. Given the sector and the relatively tight share structure here, a minimum $1.5M legacy share valuation seems completely reasonable to me. So I will be disappointed if I walk away from ECGR with anything less than 40-50 cents per share.

A couple of things I found noteworthy in the amended filing.......

1) It appears that a large institutional investor (Ionic Ventures) purchased 2M shares in the financing at 5 cents.

2) In the original filing there is a clause that prohibits ECGR from using any type of floorless financing until all of the debt owed to the consultant is paid off. If you scroll all the way to the bottom of yesterday's amended 8-K, there is a pretty interesting modification to the debt agreement between ECGR and the consultant (Coral Investment Partners -- Erik Nelson). That modification actually goes one step further and extends the ban on toxic financing for as long as Coral has ownership of any ECGR shares.......

UMFGD/RTGC...added prior to reverse split.......

I added to my position at .0055 (16.5 cents post-split) just prior to the 1:30 reverse split. The overall setup and company that is coming in here (Ridder Trader Group) does look potentially very interesting. I was hoping to get a better idea of what the exact post-split structure of the reverse merger and any potential dilution might like but I have been unable to get a response from the consultant (see post below). So absent any additional press releases that would provide more details, I might not get those answers until the next periodic report or two, which should come sometime in March/April.

Best case scenario: Ridder Trader actually owns the 5.6+M control shares, which would dramatically improve the chance of seeing some really nice upside. Worst case scenario: The consultant or another intermediary retains those control shares, which would make it somewhat more difficult to see a home run on this investment.

In addition to the video I included in the post below, there is an interesting video interview that the Ridder President did in early December....

https://fb.watch/qcogZN3eoM/

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173579220

FWFW(.083)...potentially interesting development......

Increased my position in FWFW at sub-30 cent prices in early February. It might be worth monitoring this stock a little more closely from this point forward. Since early January I have noticed a pretty interesting development going on with Flywheel Financial Strategy (which is either directly or indirectly the parent company of FWFW). I don't know to what extent (if any) that FWFW will be involved in this development. But if there is any significant involvement, and given how difficult it can be to accumulate shares of this stock, it would not be surprising at all to see a pretty nice move higher in FWFW.

I have been monitoring the social media posts of CEO Roy Tang (Tang Siu Fung) for quite awhile. In early January 2024 on his Instagram account he started posting some things that immediately caught my attention. Flywheel Financial and Astra (also known as Guangzhou Xinglun Safety Industrial Co., Ltd) were forming a new company involved in artificial intelligence, commercial and industrial robots, 3D printing, etc. This kind of perked my interest because Astra happens to be in some areas of business similar to what FWFW is currently involved in. The name of the new company is Fastra Global Holdings Limited. Every indication from his posts suggested they believe Fastra is going to be well-positioned to become a large/influential company in the areas of AI/robotics with sights on a Nasdaq listing. In one of the posts he mentioned that Steven Hoffman (well-known venture investor and CEO of Founders Space) was involved in some way. I found out a couple of days ago that Hoffman is a co-founder of this new company.

Flywheel Financial and Astra held a celebration event on January 20. Interesting to note that two days before this event FWFW filed an 8-K announcing that Lu Yeqin has been appointed Chief Technology Officer of FWFW. Lu Yeqin is the Founder/CEO of Astra, and apparently he is now also the CEO of Fastra Global, according to this Roy Tang Instagram post below from a couple of days ago. Steven Hoffman is in the center of the picture, with Lu Yegin on the left and Roy Tang on the right.......



Fastra Global was one of the presenting companies at the The Microcap Conference held in New Jersey a couple of weeks ago. The person doing the presentation was Priscilla Cheng (Cheng Sin Yi). Priscilla also happens to be the secretary/treasurer of FWFW. I am not aware of any video or material available from the presentation, but this promotional material has the most information about the company that I have seen so far. It looks like they are planning to release at least two robots in Q1 2024.....

https://www.themicrocapnewsletter.com/fastra-global-holdings-limited-advanced-robotics-for-industrial-needs/

Steven Hoffman's LinkedIn post about Fastra from a couple of days ago.....



Again, as I mentioned above I don't know to what extent (if any) that FWFW will be involved in any of this. Some possible scenarios from best to worst: Fastra might go public through FWFW, or FWFW might enter into some type of distribution deal with Fastra, or FWFW plays no role in this whatsoever and eventually Fastra does an IPO on one of the exchanges here in the United States or Asia. So invest accordingly. Despite the uncertainty regarding FWFW's direction moving forward, I find the overall risk/reward pretty interesting, which is why I increased my position.

Roy Tang Instagram: https://www.instagram.com/gshfwceort/

Roy Tang LinkedIn: https://www.linkedin.com/in/roy-tang-with-ninety-percentage-plus-hit-rate-stock-picked-go-up-a8a12a176/

Priscilla Cheng LinkedIn: https://www.linkedin.com/in/priscilla-cheng-562b741b2/

Steven Hoffman LinkedIn: https://www.linkedin.com/in/captainhoff/

FWFW website: https://fwat.com.hk/about-us/

TCRI(.25)...some interesting things in that 8-K.......

Since the change in management/directors back in early November, I have picked up additional shares mostly around the 15-cent area. There are obviously still a lot of question marks regarding exactly what is going to happen on the operational and financing side of things, and how this will all play out, but certainly that 8-K filed yesterday is quite interesting.

Based on the verbiage in the employment agreements, the TCRI business direction is basically identical to management's other company -- Edgemode (crypto mining, data centers, high-performance computing). Management suspended operations of Edgemode (EDGM) last year due to lack of financing for mining equipment. I am not sure if Edgemode still has any remaining viable assets/operations (like mining/computing pool contracts with existing data centers), and whether any of those things would eventually be moved into TCRI.

I think it is fairly clear/obvious that Phoenix has a pretty good idea of what is going to happen with TCRI. It would seem unlikely that Phoenix would be preparing to provide TCRI with a $75M line of credit unless all the parties involved here are reasonably aware of what each other intends to do. The equity/debt financing that management will be seeking to repay the $75M line of credit is probably going to be the most pivotal thing for TCRI. Bad terms/conditions could derail TCRI as an investment, and good terms/conditions might cause the stock to move nicely higher. A financing of this magnitude will obviously require the involvement of large institutional investors or extremely wealthy individuals. It will be interesting to see if the heavy involvement of Phoenix in TCRI (and the success/attention that Phoenix had with its IPO) plays a major role in the financing attempt.

Now, it is entirely possible that things here could turn out badly for various reasons, but I am somewhat encouraged by some of the things I saw in the 8-K. It appears to me that Phoenix has taken some precautions to help protect TCRI from some bad decisions or failure by the current management. Now, Phoenix itself could make mistakes and exercise poor judgement, but the fact that Phoenix will be monitoring things makes me a little more comfortable with my TCRI investment than if management had no supervision at all. A few things I found somewhat noteworthy.....

1) Management receives no compensation (no salary, no warrants) unless TCRI is successful in raising at least $75M. Phoenix can also terminate management's employment if certain revenue timelines are not reached.

2) There does not appear to be any cashless exercise features on the warrants that management will receive. If management wants to exercise any of the warrants, it will need to come up with the cash to do so.

3) It appears to me that Phoenix must approve any new liability for TCRI. In other words, if management wanted TCRI to enter into a convertible financing Phoenix would need to approve it first. This policy should decrease the risk of TCRI getting saddled with some type of toxic financing. From the employment agreements........

QGSI(.048)...debt settlement, revenue growth......

I picked up some sub-5 cent shares of QGSI today. Historically, QGSI has had some nice tradeable moves from this price area, and I am looking to see if history repeats itself. There is potentially considerable risk here because the company has been trying to raise $2M over the last couple of months or so. Depending on the terms/conditions of that capital raise this 5-cent price level could turn out to look pretty attractive or pretty bad. I'm crossing my fingers that it will not be some type of toxic financing. My guess/hunch is that the financing might get priced somewhere in that 5-10 cent price area, so I am willing to take a chance here and bought some shares.

The most recent comment about the financing was in the early December press release........

Primary reason(s) I took a position now is because of what was disclosed in the quarterly report filed yesterday.....

1) I think for the first time in company history the revenue showed a significant amount of quarter-to-quarter revenue growth -- from $3K in the previous quarter to $169K in the quarter ended November 30, 2023. So maybe the company is starting to see a little bit of traction building for its products.

2) The most interesting thing in the filing was a large debt settlement done at 10 cents after the quarter ended. That represented more than 30% of QGSI's total debt. It doesn't specify exactly what debt was settled (convertibles or just general corporate debt). Maybe this debt reduction is a precursor to an announcement/progress on the financing package........

MSAH(.075)...Boyue Medical RM, risk/reward stills looks attractive.......

Although the reverse merger target and structural details of the merger have not been officially announced yet, I still think the risk/reward on the MSAH shell looks pretty attractive at these sub-dime levels. Following the 7M share cancellation, the legacy share count will be around 6.9M shares. I am still anticipating that MSAH will see prices of 25 cents or higher (a legacy share valuation around $1.75M). After David Duarte (Tailored Tickers) announced the change in control around mid-December, the stock had what I think was a relatively small pop upward (less than a $1M legacy valuation), and has completely retraced those gains.



The reverse merger target is likely to be Boyue Medical Technology, which is a company involved in the light medical beauty industry in China (things like cosmetics, non-invasive anti-aging procedures, a beauty clinic chain/franchise, etc). The company has artificial intelligence technology that utilizes digital humans for 24x7 live e-commerce broadcasting.

The CEO (Liu Yue) appears to have had a very successful career in the beauty industry in China, has won numerous awards and is well-respected. She does have a hairdo that I find distracting, though. Not sure why but every time I run across her picture on the website, I find her appearance somewhat startling......



I don't know what type of revenue the company is generating, or whether they intend to include any of the 1 or 2 companies that appear to be affiliated with Boyue. The "development path" timeline that can be found on the homepage of Boyue Medical says an affiliated company had more than 100 beauty clinics open in 2012 and revenues of 360M in 2015 (not sure if that revenue number is US dollars or renminbi). The website news item (from probably 2021/2022) about the artificial intelligence tech does make this statement: We predict that the application of Boyue AI digital human in the beauty industry will generate a total market value of 48 million to 200 million in 2024.

http://www.byqingyimei.com/

UMFG(.0058)...Ridder Trader reverse merger, 1:30 RS.......

I've accumulated some shares of the UMFG shell under the .005 level. This shell/RM has not received a lot of attention. Most investors are probably turned off by the pending 1:30 reverse split and preferred shares that are convertible into 2.2B shares. Despite those risks, I'm a little bit intrigued by the potential on this play. The reverse merger target is Ridder Trading Group -- an artificial intelligence, fintech and brokerage firm with headquarters in Malaysia.

https://riddertrader.com/

The biggest problem I have in analyzing UMFG is trying to determine what number I should use for the legacy share count (either 30.5M or 200.5M). Legacy share valuation is, in my opinion, a pretty effective numbers-based analysis approach for use on shells and reverse mergers. By limiting my buys to that .005 level, I believe I have done a reasonable job of mitigating some of the risk if the legacy share count turns out to be the higher number. If it does turn out the legacy share number is 30.5M, then I have been buying this shell below a $150K legacy share valuation. I think it is completely reasonable to have a legacy share target valuation of at least $1.5-2M on this shell/RM.

Below are two articles related to Ridder's acquisition of the UMFG shell. The first article was particularly interesting to me because the verbiage states that Ridder "fully acquired" and had "full control" of the shell. My primary "concern" on UMFG is whether that information is accurate, or whether the preferred shares and that 170M newly-issued share block are actually owned by some type of intermediary not directly connected to Ridder. I tried to get confirmation that Ridder itself owned the preferred shares and the 170M shares that were issued, but the consultant on the shell never responded to questions I had. Excerpt from the first article.......

https://news.sina.com.cn/sx/2023-09-01/detail-imzkezte2977227.shtml
http://www.autodrivingweekly.com/sociology/160.html

You can find some information and videos related to Ridder in the Facebook account below. The Ridder President visited New York and the stock exchange in late December. In the interview below he talks about the listing in the United States, the MOPAI app, a possible Nasdaq/NYSE listing, mentions the possible use/partnership of its technology in the biotech industry, hopes that Ridder's share price will reach $5 within 3 years, and the company will be listed on one of the major exchanges.......

https://www.facebook.com/riddertradergroupRTG

https://fb.watch/pqMwnVLKn0/

QMEI...CEO's presentation, raising $100M, etc.......

The CEO made an appearance on a ZOOM call on December 15 and provided a presentation and information that is certainly a bit eyebrow raising. Let me preface this by saying that I don't fully understand everything he was talking about. I think most people who watch this presentation (and the entire call) are probably going to have the same level of confusion as I do on some aspects of the information he was providing. But I think it is safe to say that if some of the items he talks about materialize then calendar 2024 is shaping up to be potentially extremely interesting for QMEI.

A few of the items that caught my attention......

1) QMEI is looking to raise $100M at a $6 share valuation. When talking about the capital raise, pricing, structure, etc, he makes mention of discussions with the CFO, the company's legal team, and a "US investment bank". He presented a slide with a breakdown of what they intend to spend the money on.......


2) There is a capitalization table that shows the pre-offer and post-offer share structure. It is radically different from what we see in the QMEI filings and OTC Markets profile information. So I'm not sure if the share structure information we have been getting is just inaccurate or if there is an obvious explanation that I am just not recognizing right now........


3) There is a moment in the presentation when he says "when we open trade on the NASDAQ", and he says something about an "international qualified CEO". It almost seems to me that he might be planning to step aside from his CEO position prior to the uplisting.

4) As of mid-December Quantum Metal was in a total of 13 countries. In November the CEO attended the JCI World Congress in Switzerland where he met with representatives from at least 30 countries. Apparently the partnership or connections QMEI formed with the JCI has opened the door to a potentially extremely rapid expansion. The CEO says the company is expecting to be in 50 countries before the end of 2024.

5) When he talked about QMEI making a large investment and basically taking control of Besra Gold, he also noted that QMEI is in negotiations with a listed Canadian mining company. He said an announcement regarding this would be made "soon".

The CEO begins speaking around the 39:35 mark of this video........

WSCO(.50)...website active, AI holding/incubator company......

The website for Global AI started going active recently. The new ticker symbol will be: GLAI. Global AI will acquire or invest in privately-held artificial intelligence companies. I picked up some shares around 60 cents following the pullback in price. Probably will remain a pretty volatile stock for awhile, which should make for some decent opportunities to make (or lose) money. I have my fingers crossed that last week's $1M financing at 10 cents was somewhat of an insider or early bird special and not indicative of what any future financing deals might look like.



https://global.ai/

GRHI(.0121)...added recently, expecting RM developments......

Increased my position since the above post with buys in the .014-.019 range. The soft deadline for completion of the merger agreement was November 26, so I would expect there will be some type of announcement regarding the deal (completion, extension, termination) reasonably soon. Loot8 entered into another two MOUs this week. The MOU with APPIX Technologies looks kind of interesting to me.......



https://www.loot8.io/news.html

QMEI...jewelry stores, pharmacy, Nasdaq, etc......

I'm holding my position as well. Selling at sub-dollar prices doesn't appeal to me at all. It has been awhile since QMEI had any significant amount of buying pressure, but I would think that will eventually change. At some point there will be a corporate development that triggers interest, or that low float number will attract some momentum traders looking to run up a stock. It is very difficult to understand the CEO because of his accent, but it is pretty clear that he has high share price expectations for QMEI. Early in that video (around the 55 second mark) he mentions a 3-year price projection of $100.

I couldn't quite determine from what he is saying whether the timeline for a Nasdaq uplisting is still in 2024 or if it might get pushed out an additional year or so. I didn't jot down in my notes but I think at one point in the video he provided a much more accurate projection of the number/timeline on the jewelry outlets (versus the number/timeline I had mentioned in my previous post). Around 40-60 stores in about 2-3 years.

Also thought it was quite interesting that he disclosed QMEI had subsidiaries in the pharmacy and travel industry. That was a complete surprise to me. There seems to be a whole lot of things going on at this company that the market is completely unaware of at the moment. I'm assuming the travel subsidiary is probably a travel agency. The pharmacy subsidiary has an online presence and opened its first physical store a couple of months or so ago......

https://qmpharmacy.com/

https://www.facebook.com/qmpharmacy23

I wouldn't mind seeing Jonathan Seow (the CEO of Quantum Metal Thailand) do more presentations for the company. He is fluent in English and very easy to understand. In this video from the Thailand event on November 19, Jonathan starts speaking in English around the 52:10 mark........

https://fb.watch/oEHLIlTTkF/